Concepedia

Luca Gianni

LG

205

Publications

36.5K

Citations

78

H-Index

1980

Active since

Affiliations

Fondazione IRCCS Istituto Nazionale dei Tumori(Current)

IRCCS Ospedale San Raffaele

Fondazione Michelangelo

European Institute of Oncology

Istituti di Ricovero e Cura a Carattere Scientifico

Luca Gianni is an author at Fondazione IRCCS Istituto Nazionale dei Tumori specializing in medicine, oncology, and cancer therapeutics.

ORCID

Top concepts

Publications per year

1980–2024

205

Publications

205

Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

Martine Piccart, Marion Procter, Brian Leyland‐Jones et al. · New England Journal of Medicine · 2005 · 5.1K citations · Full text

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

Sunil Verma, David Miles, Luca Gianni et al. · New England Journal of Medicine · 2012 · 3.7K citations · Full text

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

Luca Gianni, Tadeusz Pieńkowski, Young‐Hyuck Im et al. · The Lancet Oncology · 2011 · 2.3K citations

, , +7

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

Aditya Bardia, Sara A. Hurvitz, Sara M. Tolaney et al. · New England Journal of Medicine · 2021 · 1.4K citations · Full text

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

Luca Gianni, W. Eiermann, Alexey Manikhas et al. · The Lancet · 2010 · 1.2K citations

, , +7

Rows per page

1–5 of 205